
Keywords: Integrin; Vedolizumab; FOXP3; Helios; Stat; Crohn's disease; Treg; Th1; Th2; cTFH; IL-2, IL-6, IL-7, IL-21; IBD; inflammatory bowel disease; CD; Crohn's disease; MS; multiple sclerosis; Treg; regulatory T cell; tTreg; thymically-derived Treg; pTreg; perip